Connor Iapoce

Ravulizumab therapy may enable patients with PNH to achieve activity and patient-reported outcomes comparable to the US general population.

Palopegteriparatide’s approval was based on positive data from the global Phase 2 PaTH Forward and Phase 3 PaTHway trials.

Thrombotic risk is more likely influenced by disease status than hormonal contraception exposure in women with SCD.

Interim analysis of STELLAR showed health-related quality of life domains were within a normal range after hematopoietic cell transplant for SCD.

Nipocalimab led to a substantially higher percentage of live births at 32 weeks’ gestation or later without intrauterine transfusions than the historical benchmark.

Ferritin cutoffs of 30 and 45 ng/mL notably increase the rate of iron deficiency diagnoses.

FDA approval for the Simplera™ continuous glucose monitor marks the company's first disposable, all-in-one CGM half the size of previous offerings.

A deep-learning model displayed a strong performance in accurately identifying myopia, strabismus, and ptosis using smartphone images.

Emergency department utilization patterns in people with sickle cell disease were impacted by the onset of the COVID-19 pandemic in 4 US states.

Delayed anemia treatment with ESAs was not correlated with worse renal events but elevated the risk of cardiovascular events and all-cause mortality.

Anemia is common in high-risk PCI and is independently associated with major adverse cardiovascular events and major bleeding risk.

Ocugen will initiate expanded access to OCU400 gene therapy in adults with retinitis pigmentosa prior to BLA approval.

Postprocedure endophthalmitis substantially decreased between 2000 and 2002, with prompt vitrectomy used less frequently as first-line treatment.

Our July 2024 month in review in ophthalmology includes the latest updates to the ophthalmological pipeline and a trio of studies on the treatment landscape for retinal diseases.

Our July 2024 hematology month in review examines the latest updates to the hematological pipeline and key study data informing clinical practice.

Patients with hemoglobin SS sickle cell disease type may experience a significantly elevated risk of retinal vascular occlusion.

A first-time comparison in US patients displays the protective association of DOACs over warfarin use on RVO and intraocular bleeding risk.

A teleretinal screening program improved the awareness of sickle cell retinopathy and motivated patients to visit an eye care provider.

Older patient age was linked to suboptimal anti-VEGF response for diabetic macular edema in DRCR clinical trials.

Geographic atrophy in eyes with dry AMD and macular atrophy in fellow eyes with neovascular AMD demonstrate similar growth rates.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key interviews from the American Society of Retina Specialists (ASRS) 42nd Annual Meeting.

Pre-dose IOP outcomes in eyes with DME receiving aflibercept 8 mg or 2 mg were comparable through Week 48 of the Phase 2/3 PHOTON trial.

A post hoc analysis of PHOTON showed the utility of aflibercept 8 mg in patients with DME, irrespective of baseline visual acuity.

Hesitancy with anti-VEGF biosimilars was identified in a survey among both ophthalmologists and patients with nAMD in Canada.

Across 40 clinical scenarios, ChatGPT did not provide a comprehensive response in 50% of clinical questions with nearly 30% hallucinated sources.

Patient factors trended towards an association with a higher risk of proliferative sickle cell retinopathy but did not reach statistical significance.

Intravitreal dosing of sozinibercept up to 2 mg in combination with ranibizumab or aflibercept was well tolerated and supported ≥Q8W dosing intervals.

Giroctocogene fitelparvovec achieved primary and key secondary objectives of superiority compared to routine prophylaxis in hemophilia A treatment.

A database analysis linked semaglutide use to notable reductions in the rates of diabetic macular edema and vitreous hemorrhage in diabetic retinopathy.

Presented at ASRS 2024, late-breaking RHONE-X data shows more than 90% of patients experienced the absence of DME after four years of faricimab.